Life Sciences and Pharma IP Litigation 2025

JAPAN Law and Practice Contributed by: Hirofumi Tada, Ohno & Partners

Ohno & Partners is one of the leading intellec - tual property law firms located in Tokyo, Japan. Currently, the firm has 29 attorneys highly spe - cialised in IP litigation and prosecution. Despite its relatively small size, the firm has represented many difficult litigations and has established numerous case laws before the Supreme Court and the Intellectual Property High Court. At -

torneys-at-law Mr Seiji Ohno and Mr Hirofumi Tada have handled many pharmaceutical litiga - tions of both small molecules and biologics. For example, the current Japanese antibody patent practice is largely based on the case law estab - lished by the team. The firm promises to offer its clients the highest quality total solution service in all areas of intellectual property rights.

Author

Hirofumi Tada is an exceptionally experienced patent litigator at Ohno & Partners, who is admitted to practice both in Japan and in California. His experience covers more than a hundred patent litigations and encompasses the fields of pharmaceuticals, biotechnology, chemicals, AI, IoT, information technology, and software, among other fields. He is also familiar with US patent practices as he practised in the United States at Finnegan.

Ohno & Partners Marunouchi Kitaguchi Bldg 21F 1-6-5, Marunouchi Chiyoda-ku Tokyo 100-0005 Japan

Tel: +81 3 5218 2331 Fax: +81 3 5218 2332 Email: info@oslaw.org Web: www.oslaw.org/en/

169 CHAMBERS.COM

Powered by